December 7, 2021
3 Min read
‘Dark green’ fund aims to help healthtech innovators to become global leaders
MTIP, the Swiss healthtech focused private equity firm, has today announced the closing of its MTIP Fund II, SCSp (“The fund”) at USD $250 million in capital commitments. The oversubscribed fund, which closed above its target of $225 million, continues its predecessor fund’s strategy of investing in growing and innovative healthtech companies primarily across Europe.
The fund, which is one of the few healthtech-specific private equity funds focused on Europe, provides growth capital to entrepreneurial and fast-growing digital health and digitally-connected medical device companies. MTIP Fund II is a designated ‘dark green’ fund, under Article 9 of the EU’s Sustainable Finance Disclosure Regulation, meaning its objective is to target sustainable investments.
MTIP Fund II seeks to capitalise on Europe’s rapidly expanding healthtech landscape, providing up to €25 million in funding to help promising scale-up companies become global leaders. After a strong first closing in late March of this year, MTIP has completed the final closing of its second fund above its original target with capital raised from new and existing investors, including multiple renowned institutional investors, pension funds, family offices, hospitals, and foundations.
“We are excited to announce the successful closing of our second fund and continue our mission to build the healthtech leaders of tomorrow,” said Dr. Christoph Kausch, Managing Partner at MTIP. “The trust our investors have put in us is a great endorsement of our strategy that’s built on our singular focus and proven approach to value creation.”
Dr. Andreas Schönenberger, CEO at the Swiss health insurance company Sanitas, is one of the investors in MTIP Fund II. He commented: “MTIP has unique expertise in healthtech and fosters innovation in this under-served private equity sector. Our collaboration with MTIP gives us access to innovative healthtech solutions that enable us to generate added value for our customers.”
The worldwide COVID-19 pandemic has accelerated innovation in the healthcare sector and led to the adoption of new technologies. MTIP’s investment team closely observes relevant healthcare and societal trends to source the most significant players in various markets. MTIP streamlines an exclusive flow of investment opportunities, which is enhanced by the firm’s network, its leading role in Europe, as well as its specific strategy to invest solely in healthtech companies. The company has already made five investments out of its second fund: Oviva, Trialbee, Koa Health, Intelligencia, and Mediktor.
MTIP is a fast-growing pan-European healthtech growth capital investor, based in Basel, Switzerland. We invest in digital health and digitally connected medical device companies, with offerings that provide clear health-related economic benefits. Our entrepreneurial investment team, which has complementary private equity skills and exceptional deal-making capabilities, actively works with our portfolio companies to boost growth. MTIP efficiently deploys capital to unlock value and generate attractive returns for our investors.
MTIP Invests $15 Million in Caresyntax
MTIP invested $15 million to accelerate Caresyntax's commercial growth and to expand its data-driven surgery platform.
Sailing the Waves of the Basel Healthtech Conference: A Recap and Reflection
As we conclude the Basel Healthtech Conference, we reflect on the incredible moments, insightful discussions, and transformative ideas that shaped this extraordinary event!
Empowering Women's Health: Navigating the Femtech Sector
Our new interactive guide sheds light on investment and innovation trends in the Femtech sector.
The Potential of AI in Healthcare & Data Science
Gerry Liaropoulos (Director of Data Science and Bioinformatics at Intelligencia.ai) and Jan Przybylowicz (Investment Analyst at MTIP) speak to Anja-Vanessa Peter (Communication Manager at MTIP) about the inner workings of ChatGPT and implications for the world of medicine and data science.
Employee Wellbeing at MTIP
We at MTIP understand that the physical and mental wellness of our team members has a direct impact on our overall performance.
Dealroom Report: Tooling the Physicians of the Future
European startups addressing clinical capacity bottlenecks
MTIP Office Featured in Swiss Office Blog
The MTIP office in Basel is featured in the Swiss office blog called “Büroblog Schweiz“ which provides information about interesting aspects of the office world.
Diversity, Equity, and Inclusion: The 3 Key Drivers for Success
At MTIP, we strive to create value for our investors and portfolio companies while remaining fully aware of our responsibility towards both society and the environment.
Growth Capital Decisions – An Interview with our Co-Founder & Managing Partner Dr. Christoph Kausch
What do growth capital investors look for? In the following interview, our Co-Founder and Managing Partner Dr. Christoph Kausch gives insight into growth capital decisions.
Rahel Hafner Receives Certificate in ESG Investing by CFA Institute
Congratulations to our Sustainability & Finance Manager Rahel Hafner for successfully passing the Certificate in ESG Investing by CFA Institute. Rahel is now fully equipped to guide MTIP and our portfolio companies in the fast-growing field of ESG investing in the best way possible.
What Makes a Great Founder/Investor Relationship?
Kai Eberhardt is the CEO and Co-Founder of our portfolio company Oviva. He talked to us about the founder/investor relationship and shared what he pays special attention to in this regard.
MTIP’s HealthCare Clinic 2022
At a nice and intimate setting in Basel, we invited our investors to our annual HealthCare Clinic last September 7 & 8.
Christoph Kausch selected by Real Deals as most influential for 2022
We are happy to share the news that Dr. Christoph Kausch, our Managing Partner at MTIP, made the list for Real Deals most influential for 2022.
MTIP leads €17 million financing round in virtual fertility clinic Apricity
We are delighted to announce MTIP Fund II’s newest investment in Apricity, UK’s leading virtual fertility clinic.
MTIP leads the €20 million growth financing round in LynxCare
We are delighted to announce MTIP Fund II’s sixth investment in LynxCare, the Belgian Health Data Scale-Up company.
Pioneering the use of machine learning algorithms to turbo-charge drug development
Novel therapy development is expensive, slow, and largely unsuccessful, making it critical to find new ways of bringing medicines to market. MTIP portfolio company, Intelligencia is helping pharmaceuticals and biotech to manage the risk of clinical development and optimize portfolio strategy.
The psychology of decision making
What makes a good investor? It’s a topic as old as investment itself, but will it evolve as Private Equity moves into new horizons such as digital medicine? Find out how MTIP approaches decision making for its investments in companies wanting to revolutionize healthcare.
Revolutionizing medical triage with artificial intelligence
Healthcare systems worldwide have been stretched to the limit by the COVID-19 pandemic, opening the door to AI driven revolutions in healthtech. The symptom checker, Mediktor, is leading the way.
MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments
‘Dark green’ fund aims to help healthtech innovators to become global leaders
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cyberattacks and ransomware are real threats to all kinds of businesses. Recent years have shown that they do not spare the healthcare sector. The WannaCry ransomware attack in 2017 paralyzed United Kingdom’s National Health Service (NHS) for four days straight. This event served as a wake-up call to the industry. Healthcare organizations realized that they had to take appropriate actions to ensure their IT security and integrity stays intact, even when attacked.
MTIP invests in Mediktor
Investment led by MTIP enables the Spanish healthtech company Mediktor to keep on improving their elaborate technology and expand their international presence.
SFDR Art. 8 or Art. 9? What’s the difference?
It all started on the 10th of March of this year, the day on which the ESG – Sustainable Finance Disclosure Regulation (EU) 2919/2088 came into effect. In this blog post, we will be highlighting the differences between the various classifications of assets such as Art. 6, Art. 8, and Art. 9 of the Sustainable Finance Disclosure Regulation (SFDR).
MTIP participates in Oviva’s new $80m Series C funding
Ovivia raises $80 million financing round
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
Investment led by MTIP enables the company to reduce the risk of clinical research, improve R&D productivity, and accelerate scientific breakthroughs through artificial intelligence (AI) and natural language processing (NLP).
Private Equity 101: Part one – Glossary
Are you new to the healthtech space? Maybe even the investment sector? Was that a “Yes”? Don’t worry, in the beginning, everything seems overwhelming and all the definitions and keywords are tricky to keep in mind. But there is always hope…
Leading brands revolutionize care journeys with Lumeon
Historically patient care journeys in healthcare facilities such as hospitals or clinics have often been described as fragmented. Lumeon has developed a flexible platform and series of solutions that address this problem. Learn more about the company in our latest blog post.
Trialbee – our hero in patient matching and recruiting for clinical trials
How can you keep the engagement rate of patients in clinical trials at a high level? Our portfolio company Trialbee has developed a solution for this problem with their patient recruitment and engagement platform. Learn more about the company in our latest blog post.
Digital healthcare: patient-first?
We have been collaborating with Dealroom.co, a data provider on startups, growth companies and tech ecosystems around the globe and INKEF Capital, a venture capital firm based in Amsterdam on our "Digital Healthcare Report". Today we are happy to present our results.